Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

2.46
-0.0500-1.99%
Pre-market: 2.43-0.0305-1.24%08:11 EDT
Volume:102.23K
Turnover:249.40K
Market Cap:4.52M
PE:-0.09
High:2.53
Open:2.44
Low:2.34
Close:2.51
52wk High:36.65
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.13
T/O Rate:6.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.61
PE(LYR):-0.04

Loading ...

HCW Biologics Updates Special Meeting Proxy Materials

TIPRANKS
·
1 hour ago

HCW Biologics Signs Exclusive Distribution Deal with Akron Biotech for HCW11-006 Reagent Commercialization

Reuters
·
Sep 08

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

THOMSON REUTERS
·
Sep 08

HCW Biologics Announces Special Shareholder Meeting

Reuters
·
Sep 08

HCW Biologics receives patent allowance for alopecia areata drug

TIPRANKS
·
Sep 02

HCW Biologics Wins USPTO Patent Allowance for Hcw9302 Use in Alopecia Areata Treatment

Reuters
·
Sep 02

HCW Biologics Says TGF-Β Trap-IL-15 Fusion Expands CD8+ T, NK Cells in Human Studies

Reuters
·
Aug 25

HCW Biologics files to sell 1.24M shares of common stock for holders

TIPRANKS
·
Aug 21

Cancer Immunotherapy Developer CEL-SCI's Q3 Net Loss Unchanged

Reuters
·
Aug 17

Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens

Reuters
·
Aug 15

HCW Biologics Q2 EPS $(11.58), Sales $135.568K Up From $6.550K YoY

Benzinga Earnings
·
Aug 15

HCW Biologics Q2 FY26 Net Loss Widens to $5.2 Million; Revenue Rises to $135,568

Reuters
·
Aug 15

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

THOMSON REUTERS
·
Aug 15

HCW Biologics Restates Q1 EPS, Cutting Net Income Attributable to Common Shareholders by USD 728,000

Reuters
·
Aug 15

HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified

Benzinga Earnings
·
Aug 15

HCW Biologics - Q1 2026 Financial Statements Should no Longer be Relied upon - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - Errors Constitute Material Misstatement of EPS - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - Error in Two-Class Method for EPS Calculation Identified - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - EPS of $2.19 Per Share Overstated by $0.80 Per Share for Q1 2026 - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics Says Q1 2026 Financials Cannot be Relied on Due to EPS Misstatement

Reuters
·
Aug 15